Literature DB >> 7953394

Improved survival in simulated surgical infection with combined cytokine, antibiotic and immunostimulant therapy.

E Gaar1, W Naziri, W G Cheadle, J D Pietsch, M Johnson, H C Polk.   

Abstract

A study was performed to find an ideal combination and sequence of cytokines, antibiotics and immunorestorative agents to enhance survival from serious infection. The effects of combinations of granulocyte-macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF) alpha, the immune adjuvant muramyl dipeptide (MDP) and two systemic antibiotics were studied in a validated murine model of surgical infection. A single cotton suture containing absorbed Klebsiella pneumoniae was placed into the thighs of mice to produce local and systemic infection. Control mice received a volume of subcutaneous saline equal to that of the therapeutic agent; only 18 per cent survived 9 days after infection. The survival time of mice treated with any single agent was similar to that of controls. The group given maximal combined therapy (65 mice) received GM-CSF, TNF-alpha, MDP, and ampicillin-sulbactam or cefoxitin for 6 days. The survival rate in this group 9 days after the introduction of infection was 84-90 per cent (P < 0.0001), suggesting that specific combinations of cytokines, immunostimulants and antibiotics may be useful in combating lethal infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7953394     DOI: 10.1002/bjs.1800810915

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  2 in total

1.  Development of an experimental model of infected skin ulcer.

Authors:  Masahiro Tachi; Shinichi Hirabayashi; Yoshiyuki Yonehara; Yasutoshi Suzuki; Philip Bowler
Journal:  Int Wound J       Date:  2004-04       Impact factor: 3.315

2.  Evaluation of antibiotic-loaded calcium phosphate bone cement in an cranium-infected experimental model.

Authors:  Yoshiaki Sakamoto; Hiroko Ochiai; Ikuko Ohsugi; Yoshikazu Inoue; Yoko Yoshimura; Kazuo Kishi
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-03-27       Impact factor: 1.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.